Suppr超能文献

铁螯合剂在视网膜血管疾病中的治疗潜力。

Therapeutic potential of iron chelators in retinal vascular diseases.

作者信息

Li Yan, Cheng Zi-Xuan, Luo Ting, Lyu Hong-Bin

机构信息

Department of Ophthalmology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.

Department of Ophthalmology, the People's Hospital of Jianyang, Chengdu 641400, Sichuan Province, China.

出版信息

Int J Ophthalmol. 2023 Nov 18;16(11):1899-1910. doi: 10.18240/ijo.2023.11.24. eCollection 2023.

Abstract

Iron is one of the necessary metal elements in the human body. There are numerous factors that control the balance of iron metabolism, and its storage and transportation mechanisms are intricate. As one of the most energy-intensive tissues in the body, the retina is susceptible to iron imbalance. The occurrence of iron overload in the retina leads to the generation of a significant quantity of reactive oxygen species. This will aggravate local oxidative stress and inflammatory reactions and even lead to ferroptosis, eventually resulting in retinal dysfunction. The blood-retina-retinal barrier is eventually harmed by oxidative stress and elevated inflammation, which are characteristics of retinal vascular disorders. The pathophysiology of retinal vascular disorders may be significantly influenced by iron. Recently, iron-chelating agents have been found to have antioxidative and anti-inflammatory actions in addition to iron chelating. Therefore, iron neutralization is considered to be a new and potentially useful therapeutic strategy. This article reviews the iron overload in retinal vascular diseases and discusses the therapeutic potential of iron-chelating agents.

摘要

铁是人体必需的金属元素之一。有许多因素控制着铁代谢的平衡,其储存和运输机制错综复杂。作为人体中能量消耗最大的组织之一,视网膜易受铁失衡的影响。视网膜中铁过载的发生会导致大量活性氧的产生。这将加剧局部氧化应激和炎症反应,甚至导致铁死亡,最终导致视网膜功能障碍。氧化应激和炎症加剧是视网膜血管疾病的特征,最终会损害血视网膜屏障。铁可能对视网膜血管疾病的病理生理学产生重大影响。最近发现,铁螯合剂除了具有铁螯合作用外,还具有抗氧化和抗炎作用。因此,铁中和被认为是一种新的、可能有用的治疗策略。本文综述了视网膜血管疾病中的铁过载,并探讨了铁螯合剂的治疗潜力。

相似文献

1
Therapeutic potential of iron chelators in retinal vascular diseases.
Int J Ophthalmol. 2023 Nov 18;16(11):1899-1910. doi: 10.18240/ijo.2023.11.24. eCollection 2023.
2
Research progress of iron metabolism in retinal diseases.
Adv Ophthalmol Pract Res. 2023 Feb 28;3(2):93-100. doi: 10.1016/j.aopr.2023.02.001. eCollection 2023 May-Jun.
3
Protective benefits of salvianic acid A against retinal iron overload by inhibition of ferroptosis.
Biomed Pharmacother. 2023 Sep;165:115140. doi: 10.1016/j.biopha.2023.115140. Epub 2023 Jul 8.
5
Iron-chelating agents attenuate NMDA-Induced neuronal injury via reduction of oxidative stress in the rat retina.
Exp Eye Res. 2018 Jun;171:30-36. doi: 10.1016/j.exer.2018.03.008. Epub 2018 Mar 9.
6
The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators.
Biomed Pharmacother. 2021 Apr;136:111228. doi: 10.1016/j.biopha.2021.111228. Epub 2021 Jan 13.
7
Iron toxicity as a potential factor in AMD.
Retina. 2007 Oct;27(8):997-1003. doi: 10.1097/IAE.0b013e318074c290.
8
Ferroptosis: mechanisms and advances in ocular diseases.
Mol Cell Biochem. 2023 Sep;478(9):2081-2095. doi: 10.1007/s11010-022-04644-5. Epub 2023 Jan 8.
9
Iron-mediated oxidative cell death is a potential contributor to neuronal dysfunction induced by neonatal hemolytic hyperbilirubinemia.
Arch Biochem Biophys. 2018 Sep 15;654:185-193. doi: 10.1016/j.abb.2018.07.022. Epub 2018 Jul 29.

引用本文的文献

2
Targeting ferroptosis: a new therapeutic opportunity for kidney diseases.
Front Immunol. 2024 Jul 3;15:1435139. doi: 10.3389/fimmu.2024.1435139. eCollection 2024.

本文引用的文献

1
Update on Retinal Vein Occlusion.
Asia Pac J Ophthalmol (Phila). 2023;12(2):196-210. doi: 10.1097/APO.0000000000000598. Epub 2023 Feb 14.
2
Ferrostatin-1 attenuates pathological angiogenesis in oxygen-induced retinopathy via inhibition of ferroptosis.
Exp Eye Res. 2023 Jan;226:109347. doi: 10.1016/j.exer.2022.109347. Epub 2022 Dec 9.
5
Activation of HIF-1α/VEGF-A pathway by deferoxamine ameliorates retinal hypoxia in a rat subarachnoid hemorrhage model.
Neuroreport. 2022 Nov 2;33(16):690-696. doi: 10.1097/WNR.0000000000001835. Epub 2022 Sep 19.
6
Retinopathy of Prematurity: A Global Perspective and Recent Developments.
Pediatrics. 2022 Sep 1;150(3). doi: 10.1542/peds.2021-053924.
7
Emerging Roles of the Iron Chelators in Inflammation.
Int J Mol Sci. 2022 Jul 20;23(14):7977. doi: 10.3390/ijms23147977.
8
Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Biomed Pharmacother. 2022 Sep;153:113363. doi: 10.1016/j.biopha.2022.113363. Epub 2022 Jul 11.
9
Anti-Inflammatory Effects of the Iron Chelator, DIBI, in Experimental Acute Lung Injury.
Molecules. 2022 Jun 23;27(13):4036. doi: 10.3390/molecules27134036.
10
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease.
Nat Rev Cardiol. 2023 Jan;20(1):7-23. doi: 10.1038/s41569-022-00735-4. Epub 2022 Jul 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验